{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T15:29:55Z","timestamp":1778426995843,"version":"3.51.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>When designing clinical trials, interpreting trial outcomes for guideline development or sharing decisions with patients in clinical practice, the clinical outcomes used and the implicit choices on what constitutes a clinically significant finding can vary greatly. This can lead to diversity or even inequity in care offered to patients with inflammatory bowel disease (IBD). The GRADE approach to guideline development has proposed a process to address this prospectively to solve these issues, but this has never been used in IBD. We aimed to develop the first international consensus set of outcome thresholds to establish their use in Crohn\u2019s disease and ulcerative colitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A Delphi methodology was used to develop a consensus. An online survey was conducted by inviting stakeholders from the British Society of Gastroenterology through a 2-phase process. Participants were asked to select important clinically relevant outcomes and were asked about what magnitude of the effect that they consider large, moderate, small, or trivial for each clinical trial outcome in line with the GRADE guidance. The results were fed back to all participants to ensure consensus agreement. Then, further surveys were sent to Europe and North America to ensure validity and international triangulation of the dataset. Data are presented as mean \u00b1 SD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 131 clinical stakeholders participated, including clinicians, IBD nurses, and a small number of patients with IBD. Clinical remission and serious adverse events were considered the most critical outcomes for Crohn\u2019s disease, while clinical remission and endoscopic remission were considered the most critical outcomes for ulcerative colitis. The consensus results for thresholds of small, moderate, and large outcome effect sizes were agreed on as follows: clinical remission, 11 \u00b1 6%, 20 \u00b1 8%, and 31 \u00b1 13%; endoscopic remission, 9 \u00b1 5%, 17 \u00b1 9%, and 28 \u00b1 14%; and serious adverse events 6 \u00b1 6%, 11 \u00b1 9%, and 17 \u00b1 12%, respectively. No significant differences were observed for responses for each condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the first study to develop a consensus on magnitude thresholds for outcomes in IBD. These thresholds have been used in the development of the 2024 British Society of Gastroenterology guidelines for the management of IBD but can and should also be used by study designers and, most importantly, by clinicians when discussing evidence with patients as part of shared decision making. Future work to validate these findings globally and with other groups, including patients, is needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaf085","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T16:22:16Z","timestamp":1744042936000},"page":"2798-2804","source":"Crossref","is-referenced-by-count":6,"title":["Developing IBD Outcome Effect Size Thresholds to Inform Research, Guidelines, and Clinical Decisions"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1216-5158","authenticated-orcid":false,"given":"Morris","family":"Gordon","sequence":"first","affiliation":[{"name":"Biomedical Evidence Synthesis and Translation, University of Central Lancashire , Lancashire, Preston ,","place":["United Kingdom"]}]},{"given":"Nader","family":"Shaban","sequence":"additional","affiliation":[{"name":"London Health Sciences Centre , London, Ontario ,","place":["Canada"]}]},{"given":"Vasiliki","family":"Sinopoulou","sequence":"additional","affiliation":[{"name":"Biomedical Evidence Synthesis and Translation, University of Central Lancashire , Lancashire, Preston ,","place":["United Kingdom"]}]},{"given":"Sudheer","family":"Vuyyuru","sequence":"additional","affiliation":[{"name":"London Health Sciences Centre , London, Ontario ,","place":["Canada"]},{"name":"Department of Gastroenterology, University of Western Ontario , London, Ontario ,","place":["Canada"]}]},{"given":"Shellie","family":"Radford","sequence":"additional","affiliation":[{"name":"Nottingham NIHR Biomedical Research Centre, University of Nottingham ,\u00a0 Nottingham, Nottinghamshire ,","place":["United Kingdom"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-9668","authenticated-orcid":false,"given":"Fernando","family":"Magro","sequence":"additional","affiliation":[{"name":"CINTESIS@RISE, Faculty of Medicine, University of Porto , Porto ,","place":["Portugal"]}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[{"name":"IBD Center, IRCCS Humanitas Research Hospital , Rozzano, Milan ,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, Milan ,","place":["Italy"]}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"INFINY Institute, INSERM NGERE, Department of Gastroenterology, CHRU de Nancy, Universit\u00e9 de Lorraine , Vand\u0153uvre-l\u00e8s-Nancy ,","place":["France"]}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"London Health Sciences Centre , London, Ontario ,","place":["Canada"]},{"name":"Department of Gastroenterology, University of Western Ontario , London, Ontario ,","place":["Canada"]}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8906-6908","authenticated-orcid":false,"given":"Gordon","family":"Moran","sequence":"additional","affiliation":[{"name":"Nottingham NIHR Biomedical Research Centre, University of Nottingham ,\u00a0 Nottingham, Nottinghamshire ,","place":["United Kingdom"]}]}],"member":"286","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"issue":"1","key":"2025102715473733200_CIT0001","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2022-001067","article-title":"BSG 2024 IBD guidelines protocol (standard operating procedures)","volume":"10","author":"Gordon","year":"2023","journal-title":"BMJ Open Gastroenterol"},{"issue":"9","key":"2025102715473733200_CIT0002","doi-asserted-by":"publisher","first-page":"1700081","DOI":"10.1002\/gch2.201700081","article-title":"Developing evidence to decision frameworks and an interactive evidence to decision tool for making and using decisions and recommendations in health care","volume":"2","author":"Rosenbaum","year":"2018","journal-title":"Glob Chall"},{"issue":"5","key":"2025102715473733200_CIT0003","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"issue":"3","key":"2025102715473733200_CIT0004","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol."},{"issue":"Suppl 3","key":"2025102715473733200_CIT0005","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut."},{"issue":"43","key":"2025102715473733200_CIT0006","doi-asserted-by":"publisher","first-page":"7572","DOI":"10.3748\/wjg.v27.i43.7572","article-title":"Minimum sample size estimates for trials in inflammatory bowel disease: a systematic review of a support resource","volume":"27","author":"Gordon","year":"2021","journal-title":"World J Gastroenterol."},{"issue":"3","key":"2025102715473733200_CIT0007","doi-asserted-by":"publisher","first-page":"e053246","DOI":"10.1136\/bmjopen-2021-053246","article-title":"Defining decision thresholds for judgments on health benefits and harms using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Evidence to Decision (EtD) frameworks: a protocol for a randomised methodological study (GRADE-THRESHOLD)","volume":"12","author":"Morgano","year":"2022","journal-title":"BMJ Open"},{"issue":"8","key":"2025102715473733200_CIT0008","doi-asserted-by":"publisher","first-page":"e003143","DOI":"10.1136\/bmjopen-2013-003143","article-title":"A generalised model for individualising a treatment recommendation based on group-level evidence from randomised clinical trials","volume":"3","author":"Marcucci","year":"2013","journal-title":"BMJ Open"},{"issue":"9","key":"2025102715473733200_CIT0009","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2165\/00019053-200826090-00004","article-title":"The NICE cost-effectiveness threshold: what it is and what that means","volume":"26","author":"McCabe","year":"2008","journal-title":"Pharmacoeconomics."},{"key":"2025102715473733200_CIT0010","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jclinepi.2017.05.006","article-title":"The GRADE Working Group clarifies the construct of certainty of evidence","volume":"87","author":"Hultcrantz","year":"2017","journal-title":"J Clin Epidemiol."},{"issue":"5","key":"2025102715473733200_CIT0011","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJM197507312930505","article-title":"Therapeutic decision making: a cost-benefit analysis","volume":"293","author":"Pauker","year":"1975","journal-title":"N Engl J Med."},{"key":"2025102715473733200_CIT0012","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jclinepi.2019.05.002","article-title":"Defining ranges for certainty ratings of diagnostic accuracy: a GRADE concept paper","volume":"117","author":"Hultcrantz","year":"2020","journal-title":"J Clin Epidemiol."},{"key":"2025102715473733200_CIT0013","volume-title":"Delphi Process: A Methodology Used for the Elicitation of Opinions of Experts","author":"Brown B","year":"1968"},{"issue":"2","key":"2025102715473733200_CIT0014","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jclinepi.2012.01.006","article-title":"GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol."},{"issue":"2","key":"2025102715473733200_CIT0015","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","article-title":"GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"J Clin Epidemiol."},{"key":"2025102715473733200_CIT0016","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jclinepi.2022.07.015","article-title":"GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions","volume":"150","author":"Sch\u00fcnemann","year":"2022","journal-title":"J Clin Epidemiol."},{"issue":"4","key":"2025102715473733200_CIT0017","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1053\/j.gastro.2020.06.092","article-title":"Assessment of evidence quality in Inflammatory Bowel Disease Guidance: the use and misuse of GRADE","volume":"159","author":"Gordon","year":"2020","journal-title":"Gastroenterology."},{"issue":"1","key":"2025102715473733200_CIT0018","doi-asserted-by":"publisher","first-page":"e001337","DOI":"10.1136\/bmjgast-2023-001337","article-title":"Quality of reporting inflammatory bowel disease randomised controlled trials: a systematic review","volume":"11","author":"Gordon","year":"2024","journal-title":"BMJ Open Gastroenterol"},{"issue":"1","key":"2025102715473733200_CIT0019","doi-asserted-by":"publisher","first-page":"e001483","DOI":"10.1136\/bmjgast-2024-001483","article-title":"Patients\u2019 and health professionals\u2019 research priorities for chronic pain associated with inflammatory bowel disease: a co-produced sequential mixed methods Delphi consensus study","volume":"11","author":"Gordon","year":"2024","journal-title":"BMJ Open Gastroenterol"},{"issue":"1","key":"2025102715473733200_CIT0020","doi-asserted-by":"publisher","first-page":"e0227635","DOI":"10.1371\/journal.pone.0227635","article-title":"Patient preferences for maintenance therapy in Crohn\u2019s disease: a discrete-choice experiment. Patient preferences for maintenance therapy in Crohn\u2019s disease: a discrete-choice experiment","volume":"15","author":"Hazlewood","year":"7635","journal-title":"PLoS One."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izaf085\/63163764\/izaf085.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/10\/2798\/63163764\/izaf085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/10\/2798\/63163764\/izaf085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:47:45Z","timestamp":1761594465000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/10\/2798\/8129398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":20,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5,13]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf085","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,5,13]]}}}